The EU Response to the Presence of Nitrosamine Impurities in Medicines
The unexpected detection of nitrosamine impurities in human medicines has recently seen global regulators act to understand the risks of these contaminations to patients and to limit their presence. Over 300 nitrosamines are known, many of which are highly potent mutagenic carcinogens. Regulators fi...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/6cbe2a2b5d95426d9f6833a958105120 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:6cbe2a2b5d95426d9f6833a958105120 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:6cbe2a2b5d95426d9f6833a9581051202021-11-19T06:29:49ZThe EU Response to the Presence of Nitrosamine Impurities in Medicines2296-858X10.3389/fmed.2021.782536https://doaj.org/article/6cbe2a2b5d95426d9f6833a9581051202021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmed.2021.782536/fullhttps://doaj.org/toc/2296-858XThe unexpected detection of nitrosamine impurities in human medicines has recently seen global regulators act to understand the risks of these contaminations to patients and to limit their presence. Over 300 nitrosamines are known, many of which are highly potent mutagenic carcinogens. Regulators first became aware of the presence of nitrosamines in EU medicines in 2018, with reports of detection of N-nitroso-dimethylamine (NDMA) in valsartan from one manufacturer. A subsequent EU review of all valsartan medicines was triggered by the European Medicines Agency (EMA) and was later extended to other angiotensin receptor blockers/sartans. A separate review was also started for ranitidine medicines. This was followed by an EU-wide examination of the risk of presence of nitrosamines in all human medicines. This article reflects on the investigation of the EU regulatory network into the presence of nitrosamines and the scientific knowledge informing recommendations for developers on how to limit nitrosamines in medicines.Robin RueppRoland FrötschlRobert BreamMaria FilanciaThomas GirardAndrei SpineiMartina WeiseRhys WhomsleyFrontiers Media S.A.articlenitrosamineshuman medicinessartansranitidinemetforminnitrite (NaNO2)Medicine (General)R5-920ENFrontiers in Medicine, Vol 8 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
nitrosamines human medicines sartans ranitidine metformin nitrite (NaNO2) Medicine (General) R5-920 |
| spellingShingle |
nitrosamines human medicines sartans ranitidine metformin nitrite (NaNO2) Medicine (General) R5-920 Robin Ruepp Roland Frötschl Robert Bream Maria Filancia Thomas Girard Andrei Spinei Martina Weise Rhys Whomsley The EU Response to the Presence of Nitrosamine Impurities in Medicines |
| description |
The unexpected detection of nitrosamine impurities in human medicines has recently seen global regulators act to understand the risks of these contaminations to patients and to limit their presence. Over 300 nitrosamines are known, many of which are highly potent mutagenic carcinogens. Regulators first became aware of the presence of nitrosamines in EU medicines in 2018, with reports of detection of N-nitroso-dimethylamine (NDMA) in valsartan from one manufacturer. A subsequent EU review of all valsartan medicines was triggered by the European Medicines Agency (EMA) and was later extended to other angiotensin receptor blockers/sartans. A separate review was also started for ranitidine medicines. This was followed by an EU-wide examination of the risk of presence of nitrosamines in all human medicines. This article reflects on the investigation of the EU regulatory network into the presence of nitrosamines and the scientific knowledge informing recommendations for developers on how to limit nitrosamines in medicines. |
| format |
article |
| author |
Robin Ruepp Roland Frötschl Robert Bream Maria Filancia Thomas Girard Andrei Spinei Martina Weise Rhys Whomsley |
| author_facet |
Robin Ruepp Roland Frötschl Robert Bream Maria Filancia Thomas Girard Andrei Spinei Martina Weise Rhys Whomsley |
| author_sort |
Robin Ruepp |
| title |
The EU Response to the Presence of Nitrosamine Impurities in Medicines |
| title_short |
The EU Response to the Presence of Nitrosamine Impurities in Medicines |
| title_full |
The EU Response to the Presence of Nitrosamine Impurities in Medicines |
| title_fullStr |
The EU Response to the Presence of Nitrosamine Impurities in Medicines |
| title_full_unstemmed |
The EU Response to the Presence of Nitrosamine Impurities in Medicines |
| title_sort |
eu response to the presence of nitrosamine impurities in medicines |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/6cbe2a2b5d95426d9f6833a958105120 |
| work_keys_str_mv |
AT robinruepp theeuresponsetothepresenceofnitrosamineimpuritiesinmedicines AT rolandfrotschl theeuresponsetothepresenceofnitrosamineimpuritiesinmedicines AT robertbream theeuresponsetothepresenceofnitrosamineimpuritiesinmedicines AT mariafilancia theeuresponsetothepresenceofnitrosamineimpuritiesinmedicines AT thomasgirard theeuresponsetothepresenceofnitrosamineimpuritiesinmedicines AT andreispinei theeuresponsetothepresenceofnitrosamineimpuritiesinmedicines AT martinaweise theeuresponsetothepresenceofnitrosamineimpuritiesinmedicines AT rhyswhomsley theeuresponsetothepresenceofnitrosamineimpuritiesinmedicines AT robinruepp euresponsetothepresenceofnitrosamineimpuritiesinmedicines AT rolandfrotschl euresponsetothepresenceofnitrosamineimpuritiesinmedicines AT robertbream euresponsetothepresenceofnitrosamineimpuritiesinmedicines AT mariafilancia euresponsetothepresenceofnitrosamineimpuritiesinmedicines AT thomasgirard euresponsetothepresenceofnitrosamineimpuritiesinmedicines AT andreispinei euresponsetothepresenceofnitrosamineimpuritiesinmedicines AT martinaweise euresponsetothepresenceofnitrosamineimpuritiesinmedicines AT rhyswhomsley euresponsetothepresenceofnitrosamineimpuritiesinmedicines |
| _version_ |
1718420318737924096 |